In conclusion, we showed that the inhibition of HDAC1 was responsible for pan-HDAC inhibitors enhancing the anti-cancer effects of statins; the inhibition of HDAC1 enhanced statin-induced inhibition of proliferation through a downregulation of GGTase-Iβ expression in cancer cells, but not in non-cancer primary cells. Here, HDAC1 is linked to cancer.